This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Robert Hawkins
Chief Strategy Advisor at Instil Bio


Robert Hawkins “Bob” is renowned oncologist and biotech innovator with a focus on development of novel cell and gene therapies and currently Chief Strategy Advisor to Instil Bio. Previously, Dr. Hawkins developed the methods to select high-affinity antibodies used for the development of Humira®, and acted as a founding consultant of Cambridge Antibody Technology and Oxford Biomedica. Furthermore, Dr. Hawkins led the team that developed the first phage-derived single-chain antibody to be used in a clinical trial in the world, led the first gene therapy trial for cancer in the UK, and led the team that did the first CAR-T trial in the UK. He led the largest European scientific consortium in engineered T cell therapy (ATTACK) and subsequent training and clinical programs. As a clinical investigator, Dr. Hawkins has been principal investigator on more than 20 clinical trials including several practice changing studies in kidney cancer. He founded Immetacyte Ltd as a spinout from the University of Manchester and there developed the TIL and CoStAR technologies being advanced by Instil.

Agenda Sessions

  • Optimizing Costimulatory Antigen Receptors (CoStAR) to Enhance the Efficacy of TIL Therapy